GloxosmithKline plc
Article Abstract:
GlaxoSmithKline PLC's earnings are to slow down in 2003 owing to difficulty following the merger and the numerous litigations against pharmaceutical manufacturers of generic drugs. Equity has minimal long-term capital-gains potential but investors are advised against committing at this time.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
GlaxoSmithK
Article Abstract:
The price appreciation potential of the shares of GlaxoSmithKline PLC for the years 2010-2012 is discussed. The Philadelphia, Pennsylvania-based form is a major research-based drug company which focuses on respiratory, antibacterial, and antiviral products.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2008
User Contributions:
Comment about this article or add new information about this topic:
Novartis AG
Article Abstract:
Novartis AG has stock price stability with few major patent expiration and less generic competition. Issue has little long-term capital gains potential with no outstanding products.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic: